Recently, we demonstrated that D 1 agonists can cause functionally selective effects when the endpoints of receptor internalization and adenylate cyclase activation are compared. The present study was designed to probe the phenomenon of functional selectivity at the D 1 receptor further by testing the hypothesis that structurally dissimilar agonists with efficacies at these endpoints that equal or exceed those of dopamine would differ in ability to influence receptor fate after internalization, a functional endpoint largely unexplored for the D 1 receptor. We selected two novel agonists of therapeutic interest that meet these criteria (the isochroman A-77636, and the isoquinoline dinapsoline), and compared the fates of the D 1 receptor after internalization in response to these two compounds with that of dopamine. We found that dopamine caused the receptor to be rapidly recycled to the cell surface within 1 h of removal. Conversely, A-77636 caused the receptor to be retained intracellularly up to 48 h after agonist removal. Most surprisingly, the D 1 receptor recovered to the cell surface 48 h after removal of dinapsoline. Taken together, these data indicate that these agonists target the D 1 receptor to different intracellular trafficking pathways, demonstrating that the phenomenon of functional selectivity at the D 1 receptor is operative for cellular events that are temporally downstream of immediate receptor activation. We hypothesize that these differential effects result from interactions of the synthetic ligands with aspects of the D 1 receptor that are distal from the ligand binding domain.
Introduction
The dopamine receptors are a superfamily of heptahelical G protein-coupled receptors (GPCRs) that have historically been partitioned into ''D 1 -like'' and ''D 2 -like'' subfamilies (Kebabian and Calne, 1979; Garau et al., 1978) . The dopamine D 1 receptor is a member of the ''D 1 -like'' subfamily, and couples to adenylate cyclase through stimulatory G proteins G s and G olf (Herve et al., 1993) . The early steps in the regulation of the D 1 receptor following the binding of dopamine have been addressed in model cell lines. After the binding of dopamine to the D 1 receptor, receptor phosphorylation is complete within minutes (Gardner et al., 2001 ). This can be mediated by Abbreviations: cAMP, cyclic AMP (adenosine 3 0 ,5 0 -cyclic monophosphate); A-77636, (1R,3S )-3-(1 0 adamantyl)-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyran); DA, dopamine; DNS, dinapsoline (8,9-dihydroxy-2,3,7,11b-tetrahydro-1H-naph[1,2,3-de] isoquinoline); GRK, G protein-coupled receptor kinase; HEPES, 4-(2-hydroxyethyl)-1-piperazine-ethane-sulfonic acid; RIA, radioimmunoassay; SCH23390, 7-chloro-8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine; TMx, transmembrane spanning section X.
GRKs (Gardner et al., 2001; Tiberi et al., 1996) and/or protein kinase A (PKA) (Mason et al., 2002) . Both types of kinases may facilitate D 1 desensitization, and the contribution of each to the overall extent of receptor phosphorylation and desensitization is probably highly dependent on the cell line being studied. Receptor phosphorylation allows arrestin to bind to the third intracellular loop of the receptor (Kim et al., 2004) leading to D 1 receptor internalization. Arrestin is not trafficked into the cell with the receptor, thus the D 1 receptor is considered a ''Class A'' GPCR (Oakley et al., 2000) . Following dopamine-induced internalization, the D 1 receptor is rapidly recycled back to the cell surface (Vickery and von Zastrow, 1999; Vargas and von Zastrow, 2004) . Recent studies indicate that a signal sequence within the proximal C-terminal region of the receptor mediates this process (Vargas and von Zastrow, 2004) .
The effects of D 1 agonists other than dopamine itself on regulatory events downstream of receptor activation are not well characterized. Besides heuristic interest in these questions, several of the D 1 agonists that have been tested as antiparkinson agents in human and non-human primates caused a very rapid tolerance evidenced as an almost complete loss of response within a day or so (Asin and Wirtshafter, 1993; Kebabian et al., 1992; Lin et al., 1996; DeNinno et al., 1991a; Johnson et al., 1992) . Thus, such molecular events may be important in understanding the cellular mechanisms that contribute to the development of this therapeutic tolerance. Previously, we have observed that desensitization of adenylate cyclase responsivity and receptor down-regulation are highly dependent upon the agonist used, but largely independent of adenylate cyclase activity and agonist affinity in a stably transfected C6 glioma cell line . Recently, we explored the relationship between agonist structure, receptor affinity, and efficacy of receptor internalization and adenylate cyclase activation in greater depth by constructing an HEK cell line stably transfected with a hemaglutinintagged human D 1 receptor and comparing these endpoints in 13 agonists from three different structural families. We found that D 1 agonists exhibit functional selectivity at these early endpoints following receptor activation that are apparently independent of agonist structure or binding affinity (RymanRasmussen et al., 2005) .
These results suggested the major hypothesis tested herein, that D 1 agonists are functionally selective in regulating receptor function at the endpoint of intracellular trafficking of the D 1 receptor, an endpoint that temporally lies downstream of adenylate cyclase activation and internalization, events more immediate of receptor activation. We selected two agonists of therapeutic interest, A-77636 and dinapsoline (DNS), for comparison with dopamine at this endpoint. Both of these synthetic ligands have efficacies of internalization and adenylate cyclase activation comparable to that of dopamine in the HA-hD 1 HEK cell line (Ryman-Rasmussen et al., 2005) . The isochroman A-77636 elicits profound and rapid in vivo tolerance occurring within approximately 24 h, preventing its use in Parkinson's disease therapy (Lin et al., 1996) . Conversely, DNS does not cause such tolerance in a rat model of Parkinson's disease (Gulwadi et al., 2001) . The mechanisms of tolerance are unknown, but presumably result from cellular adaptations that lie temporally downstream of receptor internalization and adenylate cyclase activation. The current data demonstrate that although these agonists cause functional changes identical to dopamine immediately following receptor binding, with time they modify D 1 receptor trafficking, and thus show a novel pattern of functional selectivity.
Methods

Materials
Dopamine and A-77636 [(À)-(1R,3S )-3-adamantyl-1-(aminomethyl)-3,4-dihydro-5,6-dihydroxy-1H-2-benzopyran hydrochloride)] were purchased from RBI/Sigma-Aldrich (St. Louis, MO). Dinapsoline (8,9-dihydroxy-2,3,7, 11b-tetrahydro-1H-naph[1,2,3-de] (Ghosh et al., 1996; Wyrick et al., 1986) . All other reagents and materials were from Sigma Chemical Company (St. Louis, MO), unless otherwise stated.
HA-hD 1 HEK model cell line
The HA-hD 1 HEK cell line was constructed as described previously (Ryman-Rasmussen et al., 2005) . Cells were maintained in DMEM-H, 10% FBS, 100 U/mL penicillin, 100 mg/mL streptomycin, and 0.6 mg/mL geneticin at 37 C and 5% CO 2 . Assay plates were coated with 4 mg/mL human fibronectin (Enzyme Research Laboratories Inc., South Bend, IN) at 37 C for 1 h or overnight, followed by addition of polylysine to 0.2 mg/mL for an additional 30 min to prevent cell loss. Coating medium was aspirated and cells were immediately plated at a density of 500e1000 cells per mm 2 .
Radioreceptor assays
HA-hD 1 receptor expression level and affinity for dopamine, A-77636, and DNS were determined by saturation binding and competition assays. Membrane homogenates from HA-hD 1 HEK cells were prepared as previously described . Receptor density and affinity of SCH23390 were measured by incubation of membrane homogenates in 0e2 nM [ 3 H]SCH23390 in 50 mM HEPES, 4 mM MgCl 2 , 0.01% ascorbic acid, pH 7.4 for 15 min at 37 C. Yohimbine and propranolol (50 nM) were included to block endogenous adrenergic receptors. Non-specific binding was determined by parallel incubations with 1 mM SCH23390. Radioreceptor assays were done using either a Molecular Dynamics/Skatron harvester and LKB 1209 RackBeta counter, or a Packard 96 Filtermate Harvester and TopCount Counter, using appropriate glass fiber filters and scintillation fluid. The total protein concentration of membrane preparations used in the saturation binding assays was determined by use of the BCAÔ assay according to the manufacturer's instructions (Pierce, Rockford, IL). Affinity of dopamine, A-77636, and DNS for the HA-hD 1 receptor was determined by competition (10 À10 to 10 À4 M) versus 0.3 nM [ 3 H]SCH23390 in the presence of 50 nM propranolol and yohimbine.
Adenylate cyclase functional potency and efficacy
Adenylate cyclase activation by dopamine, A-77636, and DNS was measured in whole HA-hD 1 HEK cells as previously described (Ryman-Rasmussen et al., 2005) . Triplicate wells in 24-well plates were untreated or incubated with increasing concentrations of dopamine, A-77636, or DNS in the presence of 500 mM IBMX at 37 C for 15 min. Duplicate wells at the highest concentration of agonist included the D 1 receptor-selective antagonist, 50 mM SCH23390, as a negative control. All wells contained 50 nM (S )-propranolol and yohimbine to antagonize endogenous b-adrenergic receptors. The reaction was quenched with 0.1 N HCl, and cAMP was quantified by a modified radioimmunoassay based on a previously published method (Harper and Brooker, 1975) .
Internalization assays
Internalization time-course assays were performed as previously described (Ryman-Rasmussen et al., 2005) . Briefly, 24-well plates of 1 d post-confluent HA-hD 1 HEK cells were adapted to treatment medium (L15 medium, 20 mM HEPES, 0.01% ascorbic acid pH 7.4) for 1 h. One plate per treatment time point was used. Each plate contained control wells for no drug (N ¼ 6), drug plus antagonist (N ¼ 2), and drug alone (N ¼ 4 per drug). Dopamine, A-77636, or DNS were added to cells a final concentration of 10 mM. For wells containing drug plus antagonist, the final antagonist concentration (SCH23390 or butaclamol) was 50 mM. (S )-Propranolol and yohimbine were included in all wells at a final concentration of 50 nM to block endogenous adrenergic receptors. Plates were incubated for 0e120 min in a 37 C water bath, rapidly cooled on ice, and fixed in 4% paraformaldehyde buffered with 0.1 N sodium phosphate prior to analysis for cell surface receptors by RIA vs. the HA-epitope. Internalization doseeresponse assays were performed by treating HA-hD 1 HEK cells with increasing concentrations (10 À10 to 10 À3 M) of dopamine, A-77636, or DNS at 37 C for 1 h in the presence of 50 nM (S )-propranolol and yohimbine in (N ¼ 4). All assays also contained control wells for no agonist (N ¼ 6) and 10 mM agonist plus 50 mM of the antagonist, SCH23390 (N ¼ 2 per drug). At the end of the incubation period, cells were fixed, and processed for a cell surface RIA of HA-hD 1 using a primary antibody for the HA epitope as previously described (Ryman-Rasmussen et al., 2005) . All data were expressed as a percentage of untreated controls.
Assays for cell surface receptor recovery
Twenty-four-well plates of 1 d post-confluent HA-hD 1 HEK cells were adapted to treatment medium (DMEM-H medium, 20 mM HEPES, 0.01% ascorbic acid pH 7.4) for 1 h. One plate per treatment time point was used. Each plate contained control wells for no drug (N ¼ 6), and drug and antagonist (N ¼ 2 per drug) in addition to drug treatment wells (N ¼ 4 per drug). Dopamine, A-77636, or DNS were added to a final concentration of 10 mM. For wells containing drug and antagonist, the final antagonist concentration (SCH23390 or butaclamol) was 50 mM. (S )-Propranolol and yohimbine were included in all wells at a final concentration of 50 nM to block endogenous adrenergic receptors. Plates were incubated for 1 h at 37 C and 5% CO 2 . Drug treatment medium was then aspirated, and cells were rinsed once with sterile PBS prior to incubation in treatment medium without drug from 0 to 48 h. Cells were then rapidly cooled on ice, and fixed in 4% paraformaldehyde buffered with 0.1 N sodium phosphate prior to analysis for cell surface receptors by RIA for the HA epitope as previously described (Ryman-Rasmussen et al., 2005) . Protein synthesis inhibition studies with 5 mM actinomycin D (Calbiochem) were performed similarly, with the antibiotic added to the medium after agonist removal.
Biotinylation studies
A modification of a previously published procedure was followed (Pan et al., 2003) . EZ-Link Sulfo-NHS-SS-BiotinÔ (Pierce, Rockford IL) was freshly dissolved at 4e5 mg/mL in 20 mM sodium phosphate buffer with 120 mM NaCl, pH 8.0 (at 4 C). Twelve-well plates of 1 d post-confluent HA-hD 1 HEK cells were washed twice with cold PBS, and biotinylated with 0.5 mL of reagent for 60 min on ice. The reaction was quenched by addition of 1% BSA and 10 mM glycine in sodium phosphate/NaCl for 10 min. The biotinylated cells were rinsed twice with cold PBS, and adapted for 1 h at 37 C in L15 medium with 20 mM HEPES, 0.01% ascorbic acid, pH 7.4. Dopamine was added to the drug treatment wells to a final concentration of 10 mM, with propranolol and yohimbine present at 50 nM each. Plates were incubated for 1 h at 37 C. Cells then were washed twice in cold PBS, and biotinylated cell surface receptors were cleaved by two rounds of incubation in fresh 150 mM reduced glutathione (GSH)/150 mM NaCl pH 8.8e8.9 (at 0 C) on ice for 15 min. Cells were rinsed twice with cold PBS, and drug free medium added, after which they either were placed on ice (0 h) or incubated an additional 1 h at 37 C. At the end of the incubation, cells were returned to ice. Cells were washed twice in cold PBS, and another two rounds of incubation in fresh 150 mM GSH/150 mM NaCl pH 8.8e8.9 (at 0 C) were performed in wells assaying for recycled, biotinylated receptor. Cells were lysed in 1 mL 10 mM HEPES, 2 mM EDTA, 0.5% Triton X-100, 0.1% SDS pH 7.4 with 0.5 mM PMSF, passed through a 26G needle, and incubated an additional 1 h at 4 C to solubilize receptors. Samples were centrifuged at 14,000 Â g for 15 min. A 20 ml aliquot of the supernatant was saved for determination of protein concentration, and 900 ml of the supernatant was transferred to new 1.5 mL tubes containing 75 mL of ImmunoPure Immobilized Avidin (Pierce Biochemical, Rockford IL). Binding to the avidin resin proceeded for 2 h on a rotating platform at 4 C. Avidin resin was washed twice with lysis buffer and resuspended in 70 mL of Laemmli buffer. Based on protein content prior to resin binding, approximately 35 ml of each sample was separated on a 4e12% denaturing polyacrylamide gel (Novex/Invitrogen), and blotted onto a PVDF membrane. Samples were blotted to a primary HA.11 antibody (Covance, Inc, from mouse raw ascites) at a 1000-fold dilution followed by detection with a secondary rabbit anti-mouse antibody conjugated to horseradish peroxidase (BioRad). Bands were revealed by chemiluminescent detection (ECLÔ System, Amersham) and exposure to film (BioFilm, Denville Scientific). S]Methionine-labeled cells were lysed in 10 mM HEPES, 2 mM EDTA, 0.5% Triton X-100, 0.1% SDS, pH 7.4, and an aliquot counted on a beta counter (RackBeta). Similarly treated, non-radioactive cells were washed twice with PBS. MTT (thiazolyl blue) was added to DMEM at 250 mg/mL, and applied to cells for 15 min. Cells were rinsed twice with PBS. DMSO was added to the wells to solubilize the precipitate and plates were placed on a rocker platform for 15 min. Aliquots from the wells were read in a spectrophotometer (BioRad) at 595 nm (Twentyman and Luscombe, 1987 Six-well-plates of 85% confluent HA-hD 1 HEK cells were starved for 6e8 h in methionine-free DMEM medium (Specialty Media/Cell and Molecular Technologies, Inc.) containing 100 U/mL penicillin, 100 mg/mL streptomycin, and 0.6 mg/mL geneticin. ''Starving medium'' containing 10% FBS, 10 mM cold methionine, and 0.02e0.04 mM [
35 S]methionine (Amersham-Pharmacia) were added to the cells for 18 h. After labeling, cells were washed three times with sterile PBS, and equilibrated in DMEM-H medium, 20 mM HEPES, 0.01% ascorbic acid, pH 7.4, containing 0.6 mM cold methionine. Drug treatment and recovery studies were done as described earlier, except methionine levels in the medium were maintained at 0.6 mM (normally 0.2 mM). At the end of the recovery studies, cells were rinsed twice with cold PBS, lysed in RIPA buffer with 0.5 mM PMSF containing 100 U/mL DNase and 1 mg/mL RNase (Boehringer Mannheim), and scraped into 1.5 mL tubes. Tubes were incubated at 4 C on a rotary platform for 1 h to solubilize receptors and digest nucleic acids. Tubes were centrifuged at 14,000 Â g, and 800 ml was transferred to new 1.5 mL tubes. A 20 mL aliquot was saved for determination of protein content.
35
[S]Met-HAhD 1 was immunoprecipitated by a procedure similar to one published previously (Tiberi et al., 1996) . Twenty microliters of Protein G-Sepharose (Amersham Pharmacia) were added to each tube, and the tubes were incubated at 4 C on a rotary platform for 1 h to pre-clear the supernatant. The supernatant again was transferred to a new tube, a 100-fold dilution of the HA.11 primary antibody was added to each tube, and samples were incubated for 2 h at 4 C on a rotary platform. Fifty microliters of Protein G-Sepharose was added to each tube, and incubation continued for 1 h. Immunoprecipitated samples were washed three times with RIPA, and the immunoprecipitate resuspended in 25 mL Laemmli buffer. The same amount of total protein (ca. 25 mL) was loaded on 4e12% denaturing polyacrylamide gel (Novex/Invitrogen), and the gel run according to the manufacturer's instructions. The gel was fixed for 1 h in a 20% methanol, 10% acetic acid solution, and dried on a gel drier (BioRad). Dried gels were exposed to PhosphorImager plates (Molecular Dynamics/Amersham Biosciences, Piscataway, NJ) and exposed for 2e4 days. Images were scanned on a Typhoon Imager (Molecular Dynamics), and band densities quantified with ImageQuantÔ (Amersham Biosciences) software based on average number of pixels per band.
Confocal microscopy
HA-hD 1 HEK cells were grown to 50% confluency on glass coverslips coated with fibronectin and polylysine in 24-well plates. Cells were treated in duplicate with either dopamine, A-77636, or DNS (all at 10 mM) for 1 h in the presence of 50 nM (S )-propranolol and yohimbine, as described above. Cells were rinsed with PBS, and returned to the incubator for assessment of cell surface recovery at 1 h, 12 h and 48 h, as described above. At the end of the recovery assay, cells were fixed in ice-cold, freshly made methanolfree 4% paraformaldehyde buffered in 0.1 N sodium phosphate (pH 7.4) on the bench for 30 min. Fixed cells were rinsed twice with PBS, and permeabilized with 0.3% Triton X-100 in DMEM/50 mM HEPES/10% FBS for 30 min on ice to allow antibody access to receptors on the cellular interior. Permeabilized cells were blocked with 5% BSA in DMEM/50 mM HEPES/10% FBS for 30 min, and incubated with a 1:1000 dilution of the HA.11 primary antibody (from mouse raw ascites, Covance, Inc.) as described above. Detection was by 1 h incubation with a secondary rat anti-mouse antibody conjugated to the Cy3 fluorophore (Jackson Immunolabs). Coverslips were rinsed with PBS, and wet-mounted with DAPI-containing VectashieldÔ medium (Vector Labs, Inc.). Slides were scanned in 0.6 mm steps on an upright Leica SP2 confocal microscope with a 63Â (oil) Plan Apo objective (NA 1.4e0.6). The DAPI fluorophore was excited with a 351/364 nm UV laser line and the cy3 fluorophore with a 568 nm krypton laser line. Detection was in tunable channels optimized for the emission of these fluorophores, with no observable fluorophore overlap. Images represent the cellular interior, approximately midway through the thickness of the cells. Data are representative of three independent experiments conducted at different times.
Molecular modeling
We predicted the three-dimensional structure of human dopamine D 1 receptor using the MembStruk method (Trabanino et al., 2004) . We then used the HierDock ligand docking method (Vaidehi et al., 2002) to locate the binding region for dopamine, for the two stereoisomers of dinapsoline and for four diastereomers of A-77636. We then predicted the details of the binding site for these ligands (allowing protein side chains to change and the backbone to relax), and calculated their binding energies (details of the structure and binding site to be published elsewhere).
Displacement radioreceptor assay
HEK 293 cells stably expressing the hD 1 -wild-type receptor were harvested to produce membranes for use in receptor binding assays. The 100 mM culture dishes containing the HEK cells were washed with ice cold PBS 1Â and then lysed for w15 min. with 3 mL ice cold lysis buffer (10 mM Hepes, pH 7.4). Cells were scraped, transferred to centrifuge tubes and spun at 28,000 Â g for 20 min. Pellets were then transferred to a Wheaton Glass/Teflon homogenizer in 10 mM Hepes buffer, and homogenized five times. Homogenization and centrifugation was repeated for a total of two times. The final pellet was resuspended in storage buffer (20 mM Hepes, 250 mM sucrose, pH 7.4), aliquoted in 1 mL microcentrifuge tubes and snap-frozen. Membrane aliquots were stored at À80 C until use. For use, membranes were thawed, washed, resuspended in assay buffer (50 mM HEPES/4 mM MgCl 2 , pH 7.4), and then divided into four aliquots of 500 mL each. The following was added to each aliquot at a final concentration of 10 mM: (I) A-77636; (II) dinapsoline; (III) dopamine; and (IV) buffer only. All samples were incubated at 37 C for 15 min. Upon termination of the incubation, each sample was washed twice by centrifugation at 5000 Â g for 5 min and resuspended in buffer. Each aliquot was then resuspended in 5 mL of buffer containing phenylmethanesulfonyl fluoride, and incubated for 60 min at 37 C. The samples were washed once more by centrifugation and resuspended in assay buffer. Samples (250 mL) were then tested for binding capacity (500 mL final assay volume) using 0.5 nM and 5 nM [ 3 H]SCH23390 (i.e., 1 Â K D and 5 Â K D ) to label D 1 receptors. Half of the tubes also contained 1 mM unlabeled SCH23390 to estimate non-specific binding. Binding was initiated by the addition of tissue to the tubes, and after incubation for 15 min at 37 C, the reaction was terminated by filtering with ice-cold buffer on a Packard Filtermate cell harvester (Packard Instruments, Downers Grove, IL). Radioactivity was measured using a Packard TopCount Microplate Scintillation and Luminescence Counter.
Data and statistical analysis
Affinity data were fit first to a sigmoidal model of variable slope. The data then were resolved assuming a two-site model, to yield a K D(high) and K D(low) and percent of sites in each state. K 0.5 values were calculated from the IC 50 s using the bimolecular competitive model from Cheng and Prusoff (1973) . The data for adenylate cyclase potency were expressed as the percentage of cAMP produced at the highest concentration of agonist used and the data for internalization potency expressed as percentage cell surface receptors of untreated controls. The data for both of these functional endpoints were fit to a sigmoidal doseeresponse curve. All of the analyses of these dosee response data were performed using Prism Ver. 3 or 4 (GraphPad, Inc, San Diego CA). An ANOVA with a post-hoc Tukey test was used to compare means for all internalization and recovery experiments. Significance was set at p < 0.05. All statistical testing was done using Systat Version 6 software (Systat Software Inc., Point Richmond CA).
Results
Radioreceptor assays
Saturation binding with the D 1 -selective antagonist, [ 3 H]SCH23390, in membrane homogenates indicated that the assay expression level of HA-hD 1 in this cell line is approximately 4 AE 1 pmol/mg membrane protein with a K D of 2.4 AE 0.8 nM (Fig. 1 , panel A and Table 1 ). Competition assays of dopamine, and DNS versus [ 3 H]SCH23390 were performed to determine the affinities of these compounds for the HA-hD 1 receptor (Fig. 1, panel B and Table 1 ). Dopamine and DNS best fit a two-site binding model, whereas A-77636 best fit a one-site model. These values are in agreement with results previously obtained in this model cell line (Ryman-Rasmussen et al., 2005) and those published results in rat striatal homogenates and in vitro expression systems (Ghosh et al., 1996; Lewis et al., 1998) .
Internalization time course of HA-hD 1
We characterized the temporal course of receptor internalization in response to these three agonists. Internalization for all three agonists is best described as a first-order process with a half-life of less than 10 min that reaches a steady-state by 30 min and that is stable for at least 2 h ( Fig. 2A) .
A 1-hour agonist treatment time was chosen for subsequent studies because it is midway through the observed steady state (see Fig. 2A ). At this time, steady state levels of cell surface HA-hD 1 differ significantly between agonists (Fig. 2B ). An average of 78 AE 6% of cell surface HA-hD 1 remain after treatment with dopamine, compared to 69 AE 3% after treatment with DNS, and 62 AE 3% after treatment with A-77636 (see legend of Fig. 2 for statistics) . The loss of cell surface HA-hD 1 in response to all three agonists was blocked with the D 1 selective antagonist, SCH 23390, consistent with the hypothesis that this process is mediated through activation of the D 1 receptor.
Adenylate cyclase and internalization functional potency and efficacy
Adenylate cyclase functional potency and efficacy were then assessed for all three agonists in whole cells (Fig. 3, panel A) . Dopamine had an EC 50 of 91 AE 47 nM versus 5.7 AE 1.8 nM for A-77636 and 10 AE 3.0 nM for DNS. A-77636 and DNS also had full intrinsic activity relative to dopamine, in agreement with previous work (DeNinno et al., 1991b; Lewis et al., 1998; Ghosh et al., 1996; Ryman-Rasmussen et al., 2005) . Additionally, D 1 -mediated activation of adenylate cyclase for all three agonists was completely blocked by the D 1 -selective antagonist SCH23390 (data not shown).
The rank order of efficacy in eliciting an internalization response was A-77636 > DNS > dopamine (Fig. 2, panel B) . The functional potencies of internalization also were determined for each agonist (Fig. 3, panel B) . Dopamine had an EC 50 of 600 AE 200 nM versus 80 AE 10 nM for A-77636 and 200 AE 100 nM for DNS.
3.4. Rapid recycling of HA-hD 1 to the cell surface after treatment with dopamine HA-hD 1 HEK cells were treated with 10 mM dopamine, A-77636, or DNS for 1 h, rinsed with PBS, and incubated in drug-free medium for 0e48 h. As shown in Fig. 4 , 1 h after removal of dopamine, HA-hD 1 was significantly recovered to the cell surface ( p < 0.001) to levels that are undistinguishable from control values. Conversely, no recovery of cell surface HA-hD 1 was observed at this time point after removal of either A-77636 or DNS. In fact, a significant decrease in cell surface HA-hD 1 was observed for both agonists (A-77636: p < 0.001; DNS: p < 0.05).
We hypothesized that recovery of the HA-hD 1 receptor in response to dopamine was the result of receptor recycling, based on previous reports (Vickery and von Zastrow, 1999; Vargas and von Zastrow, 2004) . We therefore used a cell impermeable, cleavable biotinylation reagent to label all cell surface receptors prior to agonist treatment. This assay allows cleavage of non-internalized receptors by glutathione (GSH) after agonist treatment, so that only the fate of internalized receptors is tracked. Internalized receptors were isolated rapidly by binding to avidin-Sepharose, and the HA-hD 1 receptor identified by Western blotting with an HA.11 antibody. Thus, the fate of internalized HA-hD 1 was tracked unequivocally, and other mechanisms (e.g., new receptor biosynthesis or export of cytosolic receptors to the surface) ruled out (Fig. 5) . Efficient labeling of cell surface HA-hD 1 was achieved (Lane 2) with low background (Lane 1), and the signal in the absence of dopamine (Lane 2) was mostly eliminated by cleavage with GSH (Lane 3). One hour after treatment with 10 mM DA and cleavage of cell surface HAhD 1 with GSH, there was internalization of HA-hD 1 (Lane 4). One hour after removal of DA from the drug treatment medium, a band corresponding to HA-hD 1 was present on the surface and interior of the cell (Lane 6). After cleavage with GSH, the remaining receptors on the interior of the cell (Lane 7) were significantly reduced relative to the total present Table 1 . Table 1 Summary of ligand binding affinity in HA-hD 1 HEK cells (Lane 6), but were slightly increased compared to control levels (Lane 5). Thus, the difference in band density between Lanes 6 and 7 can be mainly attributed to recycled HA-hD 1 . These data indicate that the majority of HA-hD 1 was recycled back to the cell surface within 1 h of removal of DA from the culture medium. Unfortunately, this method could not be applied to assess the fate of internalized HA-hD 1 in response to A-77636 and DNS, possibly as a result of hydrolysis of the disulfide bond in the cleavable biotin label in cellular compartments or from prolonged (up to 48 h) incubation times (data not shown).
3.5. Delayed responses of HA-hD 1 following removal of A-77636 or DNS
The differences observed 1 h after agonist removal from the culture medium raised questions about drug-specific differences over time. Thus, cell surface HA-hD 1 receptors were examined at later time points after removal of these agonists. Significant decreases in cell surface HA-hD 1 were observed at 24, 36, and 48 h after removal of A-77636, whereas for DNS, there was a small but significant increase in cell surface HA-hD 1 by 48 h (Fig. 6, panel A) . Comparison of the 0 and 48 h time points (Fig. 6, panel B) shows that 48 h after removal of A-77636, cell surface HA-hD 1 decreased from 65 AE 2% to 46 AE 3% ( p < 0.001). Conversely, there was a significant increase in cell surface HA-hD 1 after removal of DNS, from 73 AE 2% to 82 AE 5% ( p < 0.05). Thus, after DNS-treatment, cell surface receptors were still significantly decreased relative to untreated controls at 48 h ( p < 0.001), but were significantly greater than in cells treated with A-77636 ( p < 0.001).
Delayed recovery of HA-hD 1 is independent of new protein synthesis
The most logical explanation for an increase in cell surface HA-hD 1 density 48 h after removal of DNS from the medium is new receptor biosynthesis. Cell surface biotinylation studies could have ruled this out unequivocally, but could not be used due to hydrolysis of the label during the extended length of the experiment. Therefore, we utilized protein synthesis inhibition to determine if protein synthesis was required for receptor recovery 48 h after DNS treatment. Cycloheximide was first tried, but was too cytotoxic in this cell line at efficacious concentrations (data not shown Fig. 7, panel B , inclusion of actinomycin D in the medium after agonist removal causes no significant change were biotinylated with a cell impermeable, cleavable reagent. Biotinylated receptor was then tracked in response to DA treatment and removal in duplicate as described in Section 2. Lane labels are as follows: Background, background binding of non-biotinylated HA-hD 1 to avidin resin; Surface, total biotinylation of cell surface HA-hD 1 in the absence of DA; Con: Cleave #1, remaining cell surface HA-hD 1 after GSH cleavage in the absence of DA (a control for completeness of GSH cleavage); 1 h DA: Internal, internalized HA-hD 1 after 1 h of DA treatment and cleavage of cell surface HA-hD 1 with GSH; Con: cleave #2, remaining cell surface HA-hD 1 after second GSH cleavage (control for completeness of second GSH cleavage); Surface þ Internal, total HA-hD 1 (internalized and surface) after 1 h of DA treatment followed by 1 h of DA removal; Internal, internalized HA-hD 1 remaining after removal of cell surface HA-hD 1 by second GSH cleavage (i.e. HA-hD 1 that was not recycled). in the cell surface HA-hD 1 response resulting from treatment with dopamine, A-77636, or DNS, indicating that new protein synthesis did not mediate receptor recovery to the cell surface after removal of DNS from the culture medium.
Metabolically labeled D 1 receptors after 48 h
Although protein synthesis inhibition by actinomycin D was significant, it was not complete, and could not completely rule out new receptor biosynthesis as the mechanism by which cell surface HA-hD 1 density is recovered. It also could not rule out an alternative mechanism of export of cytosolic receptors to the cell surface. We therefore pursued pulse-chase experiments in which cellular proteins were ''pulsed'' with [ 35 S]methionine and ''chased'' with an excess of cold methionine prior to HAhD 1 receptor internalization and recovery assays in response to agonists. At the end of the recovery period, radiolabeled receptors were recovered by immunoprecipitation. Thus, the same pool of cell surface HA-hD 1 present at the time of agonist exposure could be followed over 48 h. These experiments showed that the [ 35 S]met HA-hD 1 present during agonist exposure was present 48 h after agonist removal. A similar result was obtained for untreated controls (Fig. 8, panels A and B) .
Visualization of receptor localization by confocal microscopy
The previous, quantitative assays provided valuable evidence of rapid HA-hD 1 recovery to the cell surface in response to dopamine, delayed recovery in response to DNS, and no recovery in response to A-77636. These quantitative data gave no indication of whether or not these agonists might cause differential localization of the receptor within the cell. We therefore visualized HA-hD 1 receptor localization in permeabilized cells by confocal microscopy at various time points after agonist removal from the culture medium (Fig. 9) . In the absence of agonist, the HA-hD 1 receptor was localized primarily to the cell membrane. After 1 h treatment with 10 mM dopamine, the HA-hD 1 receptor localizes to a large endosomal-like structure outside the nucleus. This occurred with a concomitant decrease in cell surface receptor staining. One hour after dopamine was removed, HA-hD 1 cell surface receptor density recovered to levels similar to that observed in untreated controls and the large endosomal-like structure was absent. Treatment of HA-hD 1 HEK with 10 mM A-77636 or DNS clearly show that surface receptors recover much slowly with DNS or not at all with A-77636. One hour after A-77636 treatment, a pronounced loss in cell surface staining for HA-hD 1 receptors was apparent and internalized receptors were localized to numerous, large endosomal-like structures on the interior of the cell. Cell surface HA-hD 1 receptor density did not recover within the 48 h observation period. One hour after DNS treatment, the HA-hD 1 receptor staining was evident in numerous, fused endosomal-like structures. A large endosomal-like structure was well-defined at 12 h and persisted at 24 h, at which time some cell surface HA-hD 1 staining was observed (data not shown). At 48 h, recovery of cell surface HA-hD 1 staining was apparent and the large endosomal-like structure was absent. Fig. 9 . Visualization of HA-hD 1 subcellular localization in response to agonist treatment and removal by confocal microscopy. HA-hD 1 staining [HA.11 primary antibody, cy3 secondary antibody converted to grayscale) is localized primarily to the cell membrane in HA-hD 1 HEK cells untreated with agonist (top row at left). The HA-hD 1 receptor is localized intracellularly 1 h after treatment with 10 mM agonist (middle row). After washing and incubation in drug-free medium, HA-hD 1 staining recovers to the cell surface 1 h after removal of dopamine (middle row at left) and is evident at 48 h after removal of DNS (bottom row at right). No recovery of cell surface HA-hD 1 staining is observed in response to A-77636 (second and third row at middle). DAPI staining for cell nuclei was removed to clearly show the receptor. Arrows indicate a large endosomal-like structure containing internalized HA-hD 1 . Data are representative of three independent experiments performed in duplicate.
Molecular modeling of the D 1 receptor
The in vitro data strongly suggested that agonist structure might be the determinate that affected the differential trafficking of the D 1 receptor. To explore the molecular factors that make A-77636 and dinapsoline traffic the D 1 receptor so differently from each other and from dopamine, we examined the differences in the D 1 binding site of dopamine, dinapsoline and A-77636. For all three ligands [S(þ)-dinapsoline, (1R,3S )-A-77636, and dopamine] the predicted binding site in the D 1 receptor involves several common elements. These include amino acids in TM3 [V100(3.29), D103(3.32), and I104(3.33)], in TM5 [S199(5.43), S202(5.46), F203(5.47)], in TM6 [F288(6.51), L291(6.54), N292(6.55)], and in TM7; [F313(7.35), V317(7.39)]. This model shows several predicted differences in the binding site for A-77636 and for dopamine. These arise from N97(3.26) on TM3; F156(4.58), V159(4.61) and W163(4.65) on TM4; A195(5.39), V200(5.44) on TM5; L291(6.54) and L295(6.58) on TM6; and F313(7.35) and V317(7.39) on TM7. These residues all have favorable van der Waals interaction with A-77636 (w6 kcal/mol more so than for dopamine). Predicted contributions to differential binding of dinapsoline and dopamine arise from I104(3.33) on TM3, F156(4.58) on TM4, V200(5.44) and F203(5.47) on TM5, and P287 on TM6, providing w3 kcal/mol better interaction energy to the D 1 receptor. Fig. 10 shows that the adamantyl group of A-77636 protrudes from the extracellular domain of D 1 receptor to interact with W163(4.65) on TM4. Thus the accessory hydrophobic adamantyl group of A-77636 may be stabilized by the extracellular loops in a way that markedly decreases ligand dissociation.
Displacement results consistent with limited dissociation of A-77636 from the D 1 receptor
It has been hypothesized that A-77636 dissociates slowly from the D 1 receptor, but this is based solely on indirect evidence that there is continued accumulation of cAMP after apparent removal of drug (Lin et al., 1996) . To provide additional direct evidence for this hypothesis, we used the strategy of radioligand displacement. Either A-77636 (1 mM) or buffer (as vehicle) was incubated with striatal membranes for 15 min, the membranes were diluted, allowed to equilibrate, washed, and then assayed for available D 1 -like binding sites. As shown in Fig. 12 , membranes pretreated with A-77636 showed a dramatic reduction in the number of available SCH23390 binding sites even after repeated washing and dilution. For the untreated membranes, or those pretreated with DA or DNS, the data fit a one-site binding model with an R 2 > 0.94 for each case. In addition, the K D for [ 3 H]SCH23390 was essentially identical for control membranes (0.51 AE 0.09 nM) versus ones pretreated with DNS (0.41 AE 0.07 nM) or DA (0.29 AE 0.05 nM), but the estimated K D for the A-77636-treated membranes had a 95% confidence interval that included 0. These results are consistent with the hypothesis from the model outlined in the previous section.
Discussion
Utilizing an HA-hD 1 HEK cell line (Ryman-Rasmussen et al., 2005) , we studied the intracellular trafficking of the D 1 receptor following binding of dopamine and two structurally dissimilar agonists, A-77636 and DNS. These agonists were similarly efficacious to dopamine in activating adenylate cyclase, and caused a similar time course of D 1 receptor internalization. Conversely, the synthetic agonists had quite different effects on events that were not temporally proximal to initial receptor occupation. The current study investigated these interesting differences in D 1 receptor trafficking using a variety of endpoints that probed cell surface D 1 receptor density in response to agonist activation.
We first characterized the time-course of internalization of the HA-hD 1 receptor in response to dopamine, A-77636, or DNS. In all cases, internalization was best described as a first-order process that reached a steady-state by 30 min and was then constant until 2 h. Whereas DNS was of similar efficacy to dopamine in causing internalization in this cell line, A-77636 caused significantly greater internalization, essentially acting like a ''super agonist'' at this function, but not at adenylate cyclase. The rank order of potency (A-77636 ! DNS [ dopamine) was similar at internalization and adenylate cyclase activation, although both A-77636 and DNS had somewhat lower potency at the former. From this data, we established for all three agonists that a 1 h treatment time at a concentration that gave high occupancy (10 mM) was sufficient to achieve steady-state levels of D 1 receptor internalization. This provided the basis for assessing post-endocytic agonist effects on receptor trafficking. The cell surface RIA data, in conjunction with confocal microscopy, showed that HA-hD 1 receptor density was recovered on the cell surface 1 h after removal of dopamine, indicating that the D 1 receptor rapidly recycled in this cell line after binding dopamine. Alternative explanations, such as export of cytosolic receptors to the cell surface or, less likely, protein biosynthesis, were ruled out by the use of a cell impermeable, cleavable biotinylation reagent. This demonstrated unequivocally that recovery of the receptor to the cell surface in response to dopamine was a result of receptor recycling. These data were consistent with earlier studies that showed that D 1 receptor is recycled rapidly back to the surface of HEK cells after dopamine removal (Vickery and von Zastrow, 1999; Vargas and von Zastrow, 2004) .
Conversely, treatment with A-77636 had a very different effect on HA-hD 1 receptor localization. After a 1 h treatment with A-77636 and removal of free drug, neither cell surface RIA, nor confocal microscopy, showed evidence of recovery to the cell surface in the next 48 h. The cell surface RIA data showed a significant decline in cell surface receptor number between 24 and 48 h after removal of A-77636. This sustained loss of cell surface receptors after the PBS wash and subsequent incubation in drug-free medium was probably due to continued receptor internalization as a result of the very slow dissociation of A-77636 from the receptor (Fig. 12 and Lin et al., 1996) . Further support for our hypothesis on the persistent receptor internalization came from pulse-chase studies with [
35 S]methionine that demonstrated that roughly half of the A-77636-treated HA-hD 1 was still present 48 h after agonist removal. Additionally, the confocal data demonstrated that A-77636 targets the receptor to numerous endosomal-like structures within the cell after 1 h of agonist treatment, structures that were still visible 48 h later. Taken together, these data indicate that the retained receptor (likely complexed with agonist) is resistant to degradation. This result is unexpected, since GPCRs that are not recycled are usually rapidly degraded. The persistence of the D 1 receptor intracellularly after treatment with A-77636 may be explained by the unusual resistance of the receptor to proteolysis (Vargas and von Zastrow, 2004) . As an aside, our data showing inability of A-77636 to dissociate from the D 1 receptor in washed membranes rules out receptor phosphorylation or other enzyme catalyzed events in the most proximal mechanism involved in this unusual trafficking.
Another unexpected finding was observed with DNS. The cell surface RIA data indicates that DNS caused very delayed recovery of cell surface HA-hD 1 receptor density. This result was supported by the confocal data that showed that DNS caused localization of the receptor to a large endosomal-like structure after 1 h of treatment. Following removal of DNS from the culture medium, this endosomal-like structure was still evident at 12 and 24 h, indicating that the receptor was not degraded. Forty-eight hours after DNS removal, this endosomal-like structure was absent and receptor staining was recovered on the cell surface.
Such a delay between receptor internalization and recovery of D 1 receptors after DNS treatment is, to our knowledge, highly unusual for a recycled GPCR. Therefore, we tested the alternative hypothesis that new protein biosynthesis was responsible for the delayed HA-hD 1 receptor recovery following DNS treatment. Use of actinomycin D resulted in 45% inhibition of protein synthesis without marked effects on cell viability. The 24e48 h interval during which protein synthesis inhibition occurred corresponded to the time during which recovery of HA-hD 1 receptor density to the cell surface was seen after DNS removal. The actinomycin D, however, had no effect on cell surface HA-hD 1 recovery. These data were consistent with the hypothesis that new protein biosynthesis was not the mechanism responsible for the cell surface recovery of the HA-hD 1 receptor following DNS removal. To provide additional evidence, we conducted pulse-chase studies with [ 35 S]methionine to determine if the original pool of HA-hD 1 present prior to DNS treatment was still present 48 h later. These data demonstrated that roughly 50% of the original receptors were indeed present at this time point. Taken together, these data strongly indicated that the delay in recovery of the D 1 receptor to the cell surface after treatment with DNS resulted from receptor recycling. The metabolic labeling studies also indicated that roughly half of the original pool of HA-hD 1 receptor present prior to treatment with all agonists was still present 48 h later, a result that was observed in both untreated cells and cells treated for 1 h with dopamine, A-77636, or DNS. This result indicates that 1 h of exposure to these agonists is not sufficient to accelerate or decelerate the rate of receptor turnover in this cell line. Slow turnover of the receptor is expected under these experimental conditions because serum and selective antibiotic are absent from the medium during this time.
The apparent ability of dopamine, A-77636, and DNS to cause differential effects in the intracellular trafficking of the D 1 receptor despite their very similar acute functional effects raises two important questions: what structural features of the ligands are responsible for the unique actions of the synthetic agonists, and what domains of the receptor are involved in this transduction. One hypothesis that should be tested further is the relative role of ligand dissociation on these trafficking changes. Dopamine, the smallest and most hydrophilic of these agonists, is the one that causes most rapid receptor recycling, whereas A-77636 and DNS more hydrophobic, and also are hypothesized to engage additional aspects of the receptor. Our data (Fig. 12) , coupled with that of Lin et al. (1996) , provide compelling evidence that A-77636 persists on the D 1 receptor for long periods of time and cannot be removed by thorough washing of membranes or by competition with excesses of antagonist. Our docking studies of A-77636 in the predicted structure of the D 1 receptor (see Fig. 10 ) support the suggestions from previous experiments (Mottola et al., 1996; Grubbs et al., 2004; Ghosh et al., 1996; Mailman et al., 1998 ) that the accessory hydrophobic adamantyl group of A-77636 is stabilized by residues near the extracellular domain sufficiently to eliminate dissociation. For example, we predict that the adamantyl group in A-77636 ligand interacts with V159, W163 on TM4 and L291, L295 on TM6, with these residues in the extracellular end of the TM regions contributing 6 kcal/mol extra stabilization (i.e., enthalpic contributions but not entropic or temperature dependent terms) to binding of A-77636, but none for dopamine. In our ligand docking calculations, we scanned the entire receptor structure for locating the possible binding site(s) of the ligands A-77636, dinapsoline, and dopamine. For dinapsoline and A-77636, apart from the binding site between TMs 3, 4, 5 and 6 described above (shown in Fig. 11, left) , we found a much weaker but perhaps significant secondary binding site for dopamine was in the intracellular portion of the inter-helical regions of TM 3, 4, 5 and 6 (see Fig. 11 , right). Although we have not characterized this site computationally, the observation suggests that there could be an allosteric binding site that recognizes the endogenous agonist to play a role in reformation of the receptor. This site might not be recognized by other agonists (such as dinapsoline and A-77636), perhaps explaining the low degree of dissociation and its subsequent effects on receptor recovery.
If further research confirms that slow dissociation of D 1 ligands is a key initiating factor that results in dramatically altered patterns of receptor trafficking, then the underlying mechanisms would be of importance. Agonist dissociation may be necessary in order for the sorting sequence in the proximal C-terminus of the D 1 receptor to interact with the endosomal sorting machinery that targets the receptor to a rapid recycling pathway (Vargas and von Zastrow, 2004) . In addition, dissociation of the agonist may be required to mediate arrestin dissociation from the receptor (or vice versa). Arrestin is not trafficked into the cell with the D 1 receptor in response to dopamine (Zhang et al., 1999) . Thus, in the case of dopamine, the D 1 receptor fits the profile of a ''Class A'' GPCR. ''Class B'' GPCRs, in contrast, are still associated with arrestin when they are internalized and the cycling of this class of receptors is much slower (Oakley et al., 2000) . An inability of the agonistereceptorearrestin complex to dissociate upon internalization, possibly as a result of stabilization of the arrestine receptor complex by a ligand like A-77636 could thus be hypothesized to ''convert'' a Class A GPCR to a Class B GPCR. The persistence of HA-hD 1 intracellularly as a result of treatment with A-77636, or to a lesser extent, DNS, provides some evidence that this could happen. It would be ideal to be able to measure the intracellular concentrations of ligand directly, but chemical methods are not adequately sensitive, and would be confounded by trapped (non-specific) ligand. Moreover, the current data show that post-treatment that includes washing and competition from antagonists cannot remove the ligand even at short time intervals, let alone after the receptor has been trafficked away from the cell surface.
In summary, this study shows that structurally dissimilar D 1 agonists that are similar in terms of their acute functional profile (e.g., adenylate cyclase) are functionally selective (Simmons, 2005; Mailman and Gay, 2004; Urban et al., 2006) in regard to long-term receptor trafficking. These findings open the door to future mechanistic studies in three distinct areas. First, what are the important ligandereceptor interactions that allow ligand-specific differentiation of long-term trafficking for compounds that otherwise appear functionally similar. Second, what intracellular mechanisms are involved in the unusual trafficking of such novel ligandereceptor complexes. Finally, do the involved intracellular mechanisms provide a clue as to the reason that A-77636 causes profound motor tolerance in vivo over a similar time course to that studied here. Investigation into all three areas will help define the universality of this phenomenon and its overall physiological importance.
